Table 1 The demographic and clinical characteristics of RA patients at baseline in the full analysis set
Characteristics | MTX + Biqi (n = 35) | MTX + LEF (n = 35) | P value |
|---|---|---|---|
Age (SD), years | 42.74 (10.35) | 44.40 (11.36) | 0.526 |
Female, n (%) | 32 (91.43) | 31 (88.57) | 0.690 |
Disease duration (SD), months | 26.12 (31.46) | 35.19 (33.45) | 0.136 |
TJC (SD), n | 8.97 (6.31) | 8.29 (6.42) | 0.544 |
SJC (SD), n | 6.03 (5.34) | 4.23 (3.03) | 0.246 |
Patient’s assessment of pain (SD), mm | 58.57 (24.54) | 56.29 (21.43) | 0.678 |
PhGADA†(SD), mm | 52.09 (25.53) | 52.00 (20.37) | 1.000 |
PaGADA†(SD), mm | 55.71 (25.61) | 53.00 (20.37) | 0.673 |
Morning stiffness (SD), min | 69.00 (53.99) | 56.03 (49.06) | 0.365 |
HAQ, mean ± SD | 1.02 (0.81) | 0.73 (0.73) | 0.116 |
hs-CRP (SD), mg/L | 12.45 (18.76) | 15.88 (17.27) | 0.259 |
ESR (SD), mm/h | 44.49 (27.20) | 54.86 (27.13) | 0.115 |
RF# (SD), U/mL | 153.55 (162.72) | 174.33 (183.97) | 0.787 |
Anti-CCP#, positive rate | 28 (84.85) | 29 (82.86) | 1.000 |
DAS28 (SD) | 4.66 (1.39) | 4.55 (1.22) | 0.742 |
NSAIDs, n (%) | 29 (82.9%) | 28 (80.0%) | 0.759 |
Glucocorticoid oral, n (%) | 6 (20.0%) | 14 (37.1%) | 0.112 |
Folic acid tablet, n (%) | 23 (65.7%) | 27 (77.1%) | 0.290 |
Antacids, n (%) | 27 (77.1%) | 26 (74.3%) | 0.780 |